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Abstract
Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack
of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this
insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator
of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been
found in carcinomas leading to tumor development and progression. In the past few years, the
knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic
approaches based on this knowledge are being developed. This review will focus on the role of
apoptotic proteins contributing to pancreatic cancer development and progression and will
demonstrate possible targets to influence this deadly disease.
Review
Pancreatic cancer is one of the most malignant tumors
with a very poor prognosis. Although pancreatic cancer
has an incidence of about 10 cases/100,000 persons it is
still the fourth male and fifth female leading cause of can-
cer-related death in the Western world [1]. Most of the
newly diagnosed patients present with an already unre-
sectable tumor stage. The 5-year survival rate of patients
with pancreatic cancer receiving surgery and chemothera-
py ranges from 1%–2% [2]. One of the reasons for this
low survival rate is the insensitivity of pancreatic cancer to
most oncologic therapies like chemotherapy, radiothera-
py and immunotherapy [3–10]. Tumor development and
progression as well as resistance to most oncologic thera-
pies result mainly from lacking response to apoptotic
stimuli.
Apoptosis or programmed cell death is a central regulator
of tissue homeostasis [reviewed in [11]]. Multicellular or-
ganisms eliminate redundant, damaged or infected cells
by apoptosis. Because chemotherapy and radiotherapy act
primarily by inducing apoptosis, defects in the apoptotic
pathway can cause cancer cell resistance [12,13]. Tumor
cells utilize multiple pathways to down-modulate apop-
tosis [14].
Apoptosis mediated by death receptors belonging to the
tumor-necrosis factor (TNF) receptor superfamily is the
best-studied pathway in cells (Figure 1) [15,16]. Members
of the TNF receptor family, TNF, Fas (Apo-1, CD95) and
TRAIL (TNF-related apoptosis-inducing ligand)-R [16]
share a common internal domain, the so-called death do-
main [17]. These receptors are activated by their natural
ligands TNFα, FasL, and TRAIL, respectively. The interac-
tion between receptor and ligand causes trimerization of
receptor followed by recruitment of FADD (Fas-associated
death domain protein) and procaspase-8 to the death do-
main forming the DISC (death-inducing signaling com-
plex) [18]. At the DISC, cleavage of procaspase-8 yields
the active form of this protease [18]. In type I cells, the
amount of activated caspase-8 is sufficient to initiate ap-
optosis via direct activation of the central effector caspase,
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Figure 1
Apoptosis mediated by death receptors of the TNF family in type I and type II cells. Apoptosis can be initiated by 
two alternative pathways: in type I cells the amount of initiator caspases is sufficent to induce executioner caspases directly or 
in type II cells the enhancing effect of mitochondria is necessary. Active executioner caspases cleave the death substrates, 
which results in apoptosis.
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caspase-3. In type II cells, the signal enhancing-effect of
mitochondria is needed to induce apoptosis [19]. The Bcl-
2 family member BID mediates activation of mitochon-
dria in response to death receptor activation. BID is
cleaved by active caspase-8 producing tBID, which is
translocated to the mitochondria [19]. tBID becomes in-
tegrated into the mitochondria membrane and induces re-
lease of cytochrome c and other apoptogenic factors from
the intermembranous space of mitochondria [20,21]. In
the cytoplasm, cytochrome c forms a complex with Apaf-
1 (apoptotic protease activating factor-1), ATP and procas-
pase-9 termed the apoptosome. Like caspase-8, caspase-9
can be considered an initiator caspase, which is activated
by cleavage at the apoptosome and activates in turn exe-
cutioner caspases, mainly caspase-3, -6 and -7 [22]. Cleav-
age of death substrates, DNA fragmentation, and cleavage
of cytoskeletal proteins finally lead to cell death [22].
This complex pathway is controlled and influenced by a
variety of different pro- and anti-apoptotic factors. The
balance of these effectors is important to ensure tissue
homeostasis. Activation or downregulation of pro- and
anti-apoptotic genes influence cancer cell viability, cancer
cell sensitivity to chemotherapy and radiotherapy, and tu-
mor development and progression (Figure 2).
This review will focus on the knowledge about deregula-
tion of apoptotic proteins and pathways in pancreatic can-
cer and possible therapeutic approaches based on these
findings.
Death receptors
As described above, apoptosis is mediated mainly by
members of the TNF death receptor superfamily proteins
including Fas (Apo-1, CD95) and TRAIL-R and their natu-
ral ligands. Deregulation of these pathways may contrib-
ute to abnormal tumor growth [23,24].
The Fas-FasL system is believed to represent one of the
main apoptotic cell death-signaling pathway [25]. Fas or
FasL over- and under-expression has been shown in a va-
riety of human carcinomas including lung [26], renal [27]
and colon cancer [28]. Findings concerning Fas receptor
expression in pancreatic cancer are contradictorily. It has
been demonstrated recently that Fas mRNA was increased
in pancreatic carcinomas [29]. Contrarily, an in vivo study
revealed that both membranous Fas and cytoplasmic Fas
receptors could not be detected invasive ductal-type pan-
creatic adenocarcinomas [30]. Together, these data sug-
gest that tumor cells can evade apoptosis by
downregulation of the Fas receptor.
In contrast to FasL, TRAIL is not toxic to normal cells [31].
Unlike other tumor cells, TRAIL receptors are highly ex-
pressed at the surface of pancreatic carcinoma cells [32].
Additionally, it has been demonstrated that repeated
treatment of different pancreatic cell lines with TRAIL
caused sustained and profound cell death [33]. These re-
sults show that the TRAIL system in principal is functional
in pancreatic cancer but is blocked at some stage down-
stream in the apoptotic pathway among which is the ex-
pression of non-functional receptors, so-called decoy
receptors. Approaches to initiate apoptosis by application
of TRAIL to cancer cells were successful in mammary car-
cinomas, intracranial gliomas and colon carcinomas [34].
However, the fact that under certain conditions this ther-
apy induces apoptosis also in normal healthy hepatocytes
causing hepatic necrosis [35] dampened the optimistic
expectations.
FAP-1
FAP-1 (Fas-associated phosphatase-1) is a non-receptor
protein tyrosine phosphatase. It has been demonstrated
that FAP-1 can block the function of Fas by interaction
with its carboxy-terminal three amino acids [10,36,37].
Cell lines resistant to Fas-mediated apoptosis strongly
overexpressed FAP-1 and it also was highly expressed in
tumor cells in pancreatic carcinoma tissues [37]. In con-
trast, Capan-1, a pancreatic cancer cell line highly sensi-
tive to Fas-mediated apoptosis, totally lacks FAP-1
expression [37]. Stable transfection of Capan-1 cells with
a FAP-1 cDNA strongly decreases the sensitivity to Fas-me-
diated apoptosis [37]. Inhibition of Golgi anterograde
transport by Brefeldin A suggested that FAP-1 could pre-
vent translocation of Fas from intracellular stores to the
cell surface [37] resulting in insufficient receptor density
at the cell surface. Modulation of FAP-1 expression or sup-
pression of its enzymatic activity may be the basis of a
novel therapy for pancreatic cancer.
The role of mitochondria
In type II cells, the apoptosis-enhancing effect of mito-
chondria is necessary to induce the full apoptotic pheno-
type. It has been demonstrated that pancreatic cancer cell
lines are type II cells [19,32,38]. The Bcl-2 family mem-
bers play the major role in this pathway.
Bcl-2 family
At the center of the cell's decision to live or to die in re-
sponse to an apoptotic signal is the Bcl-2 family of apop-
totic regulators [39]. The Bcl-2 family is the best-
characterized group of apoptosis-mediating factors and
can be divided into two main groups according to their
functional properties; anti-apoptotic proteins like Bcl-xL
and Bcl-2 and pro-apoptotic proteins, such as Bax, Bak
and Bad. Bcl-2 proteins interact with other molecules
through an α-helical domain termed BH-3 domain. This
interaction is believed to be important for regulation of
apoptosis [40].Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/6
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Figure 2
Influences of pro-and anti-apoptotic effectors on death receptor-mediated apoptosis. Apoptosis is controlled by 
several pro-(green) and anti-(red) apoptotic proteins. The balance of these proteins are important to ensure tissue 
homeostasis.
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Bcl-2 is located at the cytoplasmic face of the mitochon-
drial outer membrane, at the ER-membrane and the nu-
clear envelope and may register damage of these
compartments and affect their behavior [41]. Bcl-2 direct-
ly or indirectly prevents the release of cytochrome c from
mitochondria in a variety of tissues [41]. High expression
of Bcl-2 is found in various human tumors [42]. Interest-
ingly, it has been shown that Bcl-2 expression is normal or
even decreased in pancreatic cancer cells [43,44]. Preclinic
animal and clinical phase II studies using Bcl-2 antisense
constructs, such as G3139, in combination with different
chemotherapeutics show significant regression of differ-
ent cancers [45,46]. However, it is uncertain if this thera-
peutic approach will be successful in pancreatic cancer
showing normal or decreased Bcl-2 expression levels.
Bcl-x exists in two distinct isoforms in humans. Bcl-xL, the
longer form, functions in an anti-apoptotic manner. Bcl-
xS, the shorter form, in contrast, functions as an apoptosis
promoter. Like Bcl-2, Bcl-xL also prevents cytochrome c re-
lease from mitochondria [reviewed in [47]]. Different
studies showed that most likely every cell type is protected
by at least one member of anti-apoptotic Bcl-2-like pro-
teins. In pancreatic carcinoma cells Bcl-xL plays the most
important role in protecting from Fas and TRAIL-mediat-
ed apoptosis [32]. Furthermore, Bcl-xL is believed to bind
to Apaf-1 and may therefore inhibit the association of
Apaf-1 with procaspase-9 and thereby prevent caspase-9
activation [48]. Unlike Bcl-2, Bcl-xL is constitutively over-
expressed in pancreatic cancer cell lines highly resistant to
Fas and TRAIL-mediated apoptosis [32]. Therefore Bcl-xL
may be an ideal target for pancreatic cancer therapy. Over-
expression of Bcl-xL in cell lines with low Bcl-xL expression
like Colo357, showed complete suppression of apoptosis.
On the other hand, inhibition of Bcl-xL function by over-
expression of Bax or administration of antisense oligonu-
cleotides against Bcl-xL mRNA resulted in sensitization of
cells expressing high levels of Bcl-xL like Panc-1 or Panc-
TuI [32]. Additionally, another study revealed that Bcl-xL
antisense oligonucleotide inhibited pancreatic cancer cell
growth and caused apoptosis by reducing Bcl-xL protein
levels in different pancreatic cancer cell lines [49]. Bcl-xL
antisense nucleotides also increased the sensitivity to
chemotherapeutics like gemcitabine. This was confirmed
by another study [50]. Activation of Bcl-2 family member
Bcl-xL after repeated exposure to the chemotherapeutic
drugs 5-FU and gemcitabine contribute to chemo-resist-
ance of pancreatic cancer cells [50]. Correlation of the mo-
lecular data with clinical patient parameters revealed that
patients whose tumors exhibited no, faint, or weak Bcl-xL
expression lived significantly longer after tumor resection
than patients whose tumors exhibited moderate Bcl-xL
mRNA expression [51].
Bax is a pro-apoptotic member of the Bcl-2 family that re-
sides in the cytosol and translocates to mitochondria
upon induction of apoptosis [52]. It has been demonstrat-
ed that ectopically expressed Bax in human embryonic
kidney cells (293T cells) induced cytochrome c release
and caspase activation [53]. However, overexpression of
Bax did not influence the apoptosis rate or expression of
Bcl-2 and Bcl-xL in human pancreatic cancer cells trans-
duced with a retroviral expression vector [54]. But Bax sig-
nificantly increased the sensitivity to chemotherapeutic
drugs like gemcitabine and 5-Fu when transduced to pan-
creatic cancer cell line ASPC-1 cells [54]. Although Bax
failed to substantially increase susceptibility of the pan-
creatic cell line Colo357 towards gemcitabine in vitro, in
vivo data from a SCID mouse model suggest that pancre-
atic tumors overexpressing Bax caused higher sensibility
to gemcitabine and therefore stronger tumor regression
[B. Schniewind, unpublished data]. That indicates that
overexpression of Bax may have therapeutic application in
enhancing the efficacy of chemotherapy in pancreatic can-
cer. A recent study revealed that a binary adenoviral vector
system (Ad/GT-Bax + Ad/hTERT-GV16) using the human
telomerase reverse transcriptase (hTERT) promoter to in-
duce Bax gene expression was able to induce apoptosis in
pancreatic cancer cell lines [55]. Transduced cells not only
showed Bax overexpression but also an increased level of
caspase-3. Another study revealed that increased levels of
Bax and reduced expression of Bcl-2 are involved in the
growth-inhibitory effect of cisplatin in pancreatic cancer
cells. [56].
Another member of pro-apoptotic proteins of Bcl-2 family
is Bak. In pancreatic cancer, Bak expression and apoptosis
occur in regions of chronic inflammation surrounding the
cancer cells but not in the tumor cells themselves [57].
This may facilitate tumor growth and spread. Recent stud-
ies have demonstrated that Bad, a typical pro-apoptotic
protein of Bcl-2 family, binds with its BH3 domain to
both Bcl-2 and Bcl-xL but mediates its pro-apoptotic func-
tions through inhibition of Bcl-xL, but not Bcl-2 [58].
To restore the function of downregulated pro-apoptotic
Bcl-2 family members, there are many efforts to develop
peptides and non-peptide agents that mimic the function
of these proteins [59].
The key enzymes for arachidonic acid metabolism, lipox-
ygenases (LOXs) and cyclooxygenases (COXs) influence
the development and progression of several human can-
cers including pancreatic cancer [60]. It has been shown
that both COXs and LOXs are upregulated in human pan-
creatic cancer tissues. Inhibitor studies revealed that
blocking these enzymes inhibit pancreatic cancer growth
and induce apoptosis. Further investigations pointed out
that blockade of LOXs induce apoptosis throughMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/6
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cytochrome c release, caspase-9 activation and changes in
the levels of Bcl-2 family proteins [61].
In summary, the deregulation of Bcl-2 family both the
pro- and the anti-apoptotic proteins play a crucial role in
development, growth and expansion of pancreatic cancer.
Several approaches based on these findings have been
demonstrated to be a tool potentially influencing pancre-
atic cancer also in a clinical setting.
Caspases and caspase inhibitors
Caspases
The central component of apoptosis is a proteolytic sys-
tem involving a family of cysteine proteases termed cas-
pases. All caspases are expressed as proenzymes.
Activation involves proteolytic processing [62]. Caspases
initiate and execute cell death by inactivating anti-apop-
totic proteins, shutting down DNA replication and repair
[63], reorganization of the cytoskeleton [64] and disrup-
tion of the nuclear lamina [65].
Caspases are highly regulated by a variety of different in-
hibitors and activators. The induced proximity or oli-
gomerization model explains that caspases exist as
inactive monomers. The effectors of caspases bring the
caspases in close proximity, allowing for their intermo-
lecular autoproteolytic activation [66]. For example, acti-
vation of procaspase-8 requires association with its
cofactor FADD (Fas-associated protein with death do-
main) [67] and procaspase-9 must interact with APAF-1 to
become functional [68].
Important caspase-8 inhibitors represent the FADD-like
ICE inhibitory proteins (FLIPs) [69]. Two forms, FLIPL
(long form) and FLIPS (short form) have been character-
ized [70]. FLIPL is a structural homologue of caspase-8 but
it lacks amino acid residues that are critical for caspase ac-
tivity [70–72]. FLIPL  competes with procaspase-8 for
binding to FADD at the DISC, thus preventing caspase ac-
tivation [66]. Very interestingly, it has been shown that
FLIPL is overexpressed both in pancreatic cancer cell lines
resistant to Fas mediated apoptosis and pancreatic tumors
[73]. This may promote progression of malignant pancre-
atic tumors.
Recent studies suggest that FLIP is not simply an inhibitor
of death-receptor-induced apoptosis but it is involved in
activation of NF-κB by recruiting adaptor proteins like
TRAF [74]. NFκ-B is known to regulate several genes that
mediate tumorigenesis and metastasis [reviewed in [75]].
This may also contribute to tumor growth. Downregula-
tion of FLIP in prostate cancer cell line resulted in sensiti-
zation to Fas-mediated apoptosis [76]. Recently, it has
been demonstrated that natural and synthetic ligands of
the transcription factor PPARγ (peroxysome proliferator-
activated receptor γ) sensitize tumor cells to apoptosis by
decreasing the level of FLIP [77]. Equivalent data concern-
ing pancreatic cancer are eagerly awaited. It has been
shown that caspase expression is more or less normal in
pancreatic carcinoma. In contrast, effectors blocking cas-
pase activation or function like FLIPs are deregulated in
pancreatic cancer leading to resistance to death receptor
mediated apoptosis.
A new therapeutic approach uses somatostatin receptor
subtype 2 (sst2) to activate caspase-3 and therefore to in-
duce apoptosis in pancreatic cancer [78]. Likewise, sst2
treatment of human cancer cell lines with Diospyrin, a bi-
snaphthoquinonoid natural product, resulted in induc-
tion of apoptosis mediated via activation of caspase-3 and
caspase-8 [79].
Irofulven (MGI 114, 6-hydroxymethylacylfulvene) induc-
es apoptosis via caspase activation in pancreatic carcino-
ma cells [80].
IAP family
The inhibitor of apoptosis (IAP) family including cIAPs,
XIAP and survivin can block apoptosis through interac-
tion with members of the caspase family. IAPs are charac-
terized by a domain termed the baculoviral IAP repeat
(BIR) necessary for caspase interaction [81,82]. At least
one BIR domain is necessary for suppression of apoptosis
[83]. Another structural feature of IAPs is the presence of
a carboxy terminal RING zinc finger domain [83]. But it
seems that this domain is not always strictly required for
inhibition of apoptosis [84–87]. Overexpression of XIAP,
cIAP1, cIAP2 and survivin has been demonstrated to sup-
press apoptosis [reviewed in [83]]. The cellular function of
the IAP family members cIAP1, cIAP2 and XIAP is largely
unclear. These proteins seem to be involved in pathogen-
esis of small-cell lung cancer [88], non-small cell lung can-
cer [89], myeloid leukemia cells [90] and prostrate cancer
[91]. Concerning pancreatic cancer, there are only few
data on the involvement of cIAP1, cIAP2 and XIAP in the
pathogenesis of this type of cancer. Our own results
indicate increased levels of cIAP1, cIAP2 and XIAP in pan-
creatic cancer cell lines highly resistant to Fas- and TRAIL-
induced apoptosis (A. Trauzold, unpublished data).
Therefore, changes of expression of cIAP1, cIAP2 and
XIAP may also have a role in the pathogenesis also in pan-
creatic cancer.
Survivin
Survivin has been identified as a new member of the in-
hibitor of apoptosis (IAP) family. Survivin is characterized
by a unique structure that discriminates it from all other
members of the IAP family. It contains only a single BIR
repeat and lacks a carboxy terminal RING finger domain.
Survivin is expressed in the G2/M phase of the cell cycle inMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/6
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a cycle-regulated manner [92]. It directly binds to and in-
hibits both caspase-3 and caspase-7 activity leading to ar-
rest of apoptosis [93].
Survivin expression is not detectable in differentiated nor-
mal adult cells of any organ [94] but it is highly expressed
in a wide range of cancer tissues [95] including neuroblas-
toma [96], colorectal [97] and stomach [98] carcinoma. It
has been demonstrated recently that survivin is also fre-
quently expressed in malignant pancreatic ductal tumors
[99]. Because survivin is a potent caspase-inhibitor, its
overexpression in cancer cells is implicated in the resist-
ance to different apoptotic stimuli including chemothera-
py. Molecular manipulation of survivin expression may
enhance chemotherapy and radiation therapy not only in
pancreatic cancer.
SMAC/DIABLO
IAPs are inhibited by a protein named SMAC/DIABLO
(Second mitochondria-derived activator of caspase/direct
IAP binding protein with low pI) [100,101]. SMAC/DIA-
BLO is synthesized as a precursor protein and is imported
into mitochondria [100]. Upon cellular stress, SMAC/DI-
ABLO is released into the cytosol. In the cytosol it pro-
motes cell death by preventing IAP inhibition of caspases
[102]. Like cytochrome c, release of SMAC/DIABLO from
the mitochondria is inhibitable by Bcl-2 [100]. SMAC/DI-
ABLO could have a therapeutic application in enhancing
the effect of chemotherapeutics by binding IAPs that are
overexpressed in a variety of carcinoma cells including
pancreatic cancer. Recently it has been shown that SMAC/
DIABLO fusion peptide was able to enhance apoptosis in-
duced by diverse anticancer agents including paclitaxel,
etoposide and others in MCF-7 breast cancer cells [103].
Growth Factors
Growth factor independence is a hallmark of tumors and
is known to give cells a selective growth advantage [104].
Mutations of tumor suppressor genes and oncogenes lead
to a loss of regulation in the expression and/or activation
of both growth factors and their receptors [105]. Human
pancreatic cancer cells are reported to produce multiple
growth factors including insulin-like growth factor (IGF)
and the receptors IGF-1 receptor (IGF-1R) and IGF-2 re-
ceptor, epidermal growth factor (EGF), EGF receptor
(EGFR) and ErbB2, transforming growth factor-α (TGF-
α), and transforming growth factor-β (TGF-β), fibroblast
growth factor (FGF), vascular endothelial growth factors
(VEGF) and their receptors [106–115].
Insulin-like growth factor (IGF)
Insulin-like growth factors (IGFs), including IGF-1 and
IGF-2, are mitogenic peptides involved in the regulation
of cell proliferation, differentiation and apoptosis
[116,117]. Exogenous IGF-1 increased cell proliferation
and activated MAPK and AKT signaling pathways in pan-
creatic cell lines [118,119]. IGF-2 might function in the
switch from the quiescent to the proliferative state [120].
In multiple myeloma cells IGF-1 stimulates sustained ac-
tivation of NF-κB and AKT and upregulates a series of anti-
apoptotic proteins including FLIP, survivin, cIAP-2 and
XIAP [121].
IGF-1R shows the highest binding affinity for IGF-1, al-
though IGF-2 can also bind and activate the receptor
[117]. IGF-1R as well as IGF-1 and IGF-2 have been found
to be upregulated in pancreatic cancer [122]. This leads to
down-modulation of apoptosis and survival of cancer
cells through the PI3K/AKT pathway.
Epidermal growth factor (EGF)
Epidermal growth factor (EGF) stimulates proliferation
and differentiation in a wide range of cell types through its
corresponding receptor, EGFR. The EGFR gene is overex-
pressed in the majority of pancreatic ductal adenocarcino-
mas and human pancreatic cancer cell lines [123]. EGFR
binds EGF and TGF-α with high affinity, and both ligands
are overexpressed in pancreatic cancer [123]. Additional-
ly, the overexpression of both the EGF receptor and its lig-
and in human pancreatic cancer is associated with
enhanced tumor aggressiveness and shorter survival fol-
lowing tumor resection [124].
Treatment of pancreatic cancer cell lines with Erbitux
(IMC-C225) anti-EGFR antibody in combination with
gemcitabine and radiation resulted in complete regression
or growth inhibition of cancer cells in a preclinical setting
[125]. This combinatory treatment shows potential clini-
cal application in the treatment of pancreatic cancer in
humans.
Vascular endothelial growth factor (VEGF) and fibroblast growth fac-
tor (FGF)
Vascular endothelial growth factor (VEGF) is a potent and
specific angiogenic factor. VEGF is known to be a key play-
er for tumor growth [126,127]. Fibroblast growth factors
(FGFs) are mitogenic polypeptides that signal via FGF re-
ceptors (FGFRs). Both certain FGFs and VEGF and their re-
ceptors are overexpressed in cancer cells including
pancreatic cancer cells [111,112]. A soluble receptor for
VEGF (sVEGF) functions as a dominant-negative inhibitor
of receptor suppresses tumor angiogenesis and enhances
apoptosis of cancer cells [128]. This effect was increased
by combined use of sVEGF and a soluble FGF receptor
(sFGFR1) in lung and pancreatic cancer cell lines [129].
Transforming growth factor alpha (TGF-α)
TGF-α is structurally and functionally related to members
of the EGF family [130]. Numerous human solid tumors
express high levels of TGF-α [131]. Recent work hasMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/6
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shown that overexpression of TGF-α in liver has a dramat-
ic protective effect on Fas-mediated apoptosis in TGF-α
transformed mice. Mice with TGF-α overexpression in the
pancreas develop ductal pancreatic cancer [132]. Interest-
ingly, expression of Bcl-xL, an anti-apoptotic protein, was
greatly increased in these transgenic mice and may partic-
Figure 3
Effects causing pancreatic cancer and possible therapeutic approaches. Multiple changes of apoptotic proteins con-
tribute to pancreatic cancer development and progression. But many therapeutic approaches are developed to restore normal 
sensitivity to apoptotic stimuli and therefore to repress pancreatic cancer.
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ipate in protective role of TGF-α [133]. This may contrib-
ute to apoptosis resistance in pancreatic cancer cells.
Transforming growth factor beta (TGF-β)
TGF-β is a multifunctional cytokine regulating a broad
spectrum of cellular activity including cell-cycle control,
differentiation, and apoptosis [reviewed in [134]]. TGF-β
is a factor mediating growth inhibition and induction of
apoptosis [134,135]. TGF-β is involved in many events of
apoptotic pathways. It cooperates with Fas [136] and TGF-
α [137], down-regulates the anti-apoptotic proteins Bcl-xL
and Bcl-2 and activates caspase-1, -3, -8 and -9 [138,139].
Another mechanism of TGF-β-induced apoptosis has
been proposed following the finding that TGF-β down-
regulates NF-κB activity by the induction of the expression
of IκB α, a specific inhibitor of NF-κB [140]. TGF-β initi-
ates its cellular response by activation of specific down-
stream intracellular effectors termed SMAD proteins
[reviewed in [141]] Escape from TGF-β/SMAD-induced
apoptosis is frequently observed in tumors. Mutations
and changes of expression levels of TGF-β and SMAD pro-
teins could be observed also in pancreatic cancer tissues
[142,143]. For example, SMAD 4, a tumor suppressor in
the TGF-β signaling pathway is genetically inactivated in
about 55% of all pancreatic adenocarcinomas. Patients
with pancreatic adenocarcinomas with SMAD4 expres-
sion live significantly longer [144].
Other factors and signaling pathways
Nuclear factor of κB (NF-κB)
Nuclear factor κB (NFκB) is a sequence-specific transcrip-
tion factor that is involved in many cellular activities in-
cluding the inflammatory and immune response. NF-κB
also inhibits apoptosis by activation of several anti-apop-
totic proteins [[145], reviewed in [146]] like cIAPs, FLIPs
and the Bcl-2 family member Bcl-xL [147]. Normally, NF-
κB remains as a heterodimeric complex consisting of p50,
p65, and is kept by IκBα in an inactive state in the cyto-
plasm. A variety of stimuli like cytokines, pathogens, car-
cinogens or stress can lead to degradation of IκBα and
p50–p65 heterodimer is translocated to the nucleus,
binds the DNA at the promoter region and activates anti-
apoptotic genes [148]. It has been demonstrated recently
that NF-κB contributes to apoptosis resistance in different
cancers including pancreatic cancer [38,148]. This sug-
gests that NF-κB is an ideal target for chemotherapeutic
therapies of cancer. Inhibition of NF-κB by Gliotoxin,
MG132 or Sulfasalazine [149] sensitizes pancreatic cancer
cells to apoptosis induced by etoposide (VP16) or doxo-
rubicin. Furthermore, inhibition of NF-κB by food-de-
rived polyphenols like quercitin decreased pancreatic
cancer growth and prevented metastasis [150]. Quercitin
decreased primary tumor growth, increased apoptosis by
mitochondrial depolarization, cytochrome c release, cas-
pase 3 activation, and inhibition of NF-κB activation.
PKCµ
Protein kinases control and modulate a variety of cellular
activities. Members of the protein kinase C (PKC) family
have been shown to be involved in cell proliferation and
differentiation [151]. Screening of expression pattern of
PKC isoforms pointed out that the expression of PKCµ
correlates with the resistance to Fas-mediated apoptosis in
different pancreatic cancer cell lines [40]. Cell lines highly
resistant to Fas-mediated apoptosis show high PKCµ ex-
pression levels [40]. It has been demonstrated that PKCµ
regulates apoptosis in several cancer cells including pan-
creatic carcinoma cells [152,153]. Overexpression of
PKCµ reduces the sensitivity of the cells to apoptosis in-
duced by TNF [153]. This effect correlates with an en-
hanced expression of anti-apoptotic proteins like cIAP2,
TRAF1, cFLIP and survivin as well as increased expression
level of NF-κB dependent genes [152–154].
Survival signaling through PI3K/AKT
Survival signals like growth factors, cytokines and hor-
mones activate phosphatidylinositol 3-kinase (PI3K)
[155]. Subsequently, PI3K activates AKT/PKB [156] that
interferes with the apoptotic machinery. Activated AKT/
PKB mediate cell survival via the regulation of numerous
apoptotic relevant proteins such as the Bcl-2 family mem-
bers BAD and Bcl-xL and the transcription factor NF-κB
[157,158]. Survival signaling by AKT is counteracted by
PTEN that antagonizes the action of PI3K. PI3K and AKT
are overexpressed in a variety of cancers [159,160]. In ad-
dition, PTEN is frequently deleted in advanced tumors
[161,162]. These alterations lead to a 'constitutively ac-
tive' survival-signaling pathway that enhances the insensi-
tivity of tumor cells to apoptosis induction. Additionally,
EGFR directly influences PI3K [163]. Because PI3K
mediates survival signals, EGFR overexpression leads to a
decrease in the apoptotic response and therefore a strong-
er survival of cancer cells. Recent work has shown that the
IGF-1R suppresses apoptosis by signaling through PI3K
and AKT [120]. Activated AKT in turn phosphorylates the
intracellular transducer, Bad, which modulates the activity
of the apoptosis suppressors Bcl-2 and Bcl-xL [164]. Addi-
tionally, AKT can directly phosphorylate caspase-9, which
leads to inactivation of caspase-9 [165]. Strategies are pur-
sued that aim to block the enzymatic activity of PI3K and
PKB/AKT, in order to prevent inactivation of pro-apoptot-
ic Bad. Wortmannin was shown to be a potent inhibitor
of PI3K [160]. In several cancers including non-small-cell
lung cancer [160] and pancreatic cancer [166], treatment
of cells with wortmannin leads to inhibition of prolifera-
tion and increased apoptosis. Additionally, wortmannin
enhanced gemcitabine-induced apoptosis in human pan-
creatic cells in vitro [167] and in vivo [168]. In contrast,
studies investigating different pancreatic cancer cell lines
pointed out that the PI3K/AKT pathway is not involved in
gemcitabine-resistance [A. Arlt, unpublished data]. Nei-Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/6
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ther did the basal AKT-activity correlate with the sensitiv-
ity towards gemcitabine treatment, nor did the inhibition
of PI3K/AKT alter gemcitabine-induced apoptosis.
p53
The p53 pathway represents the molecular connection be-
tween the cell cycle and apoptosis. The p53 gene encodes
a 53-kDa nuclear phosphoprotein. p53 inhibits cell
growth through activation of cell cycle arrest and apopto-
sis [169]. The p53 gene is mutated in over 50% of human
cancers. Pancreatic cell lines showed mutations in p53 at
frequencies of 95% [170]. This enhances tumor develop-
ment and progression. Currently, many therapeutic ap-
proaches were attempted to normalize p53 function in a
variety of cancers including pancreatic cancer. Transfer of
wild-type p53 induces apoptosis and produces significant
growth suppression of pancreatic cancer in vitro and in
vivo [170–172].
Conclusion
In the past, many efforts were made to cure patients from
pancreatic cancer. Changes of expression and mutations
of apoptotic proteins are common in pancreatic cancer
cells and contribute to tumor development and progres-
sion. Consequently, pancreatic cancer has developed mul-
tiple resistance mechanisms to apoptosis. Many efforts to
restore apoptosis and thereby reducing tumor growth
were made with considerable success at least under pre-
clinical conditions (Figure 3). Future therapies have to
translate this knowledge into the clinic. They need to com-
bine various therapeutic strategies and have to modulate
selectively the sensitivity of pancreatic cancer cells to ap-
optosis without affecting normal cells.
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